At a glance
ClinicalIndex Comparison RecordN/ACompleted· 684 enrolled
Drug / intervention
Enbrel (etanercept)drug
Likely dose
Enbrel (etanercept) 25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Enbrel Special Use Result Surveillance
In Brief
An observational study evaluating Enbrel (etanercept) for Rheumatoid Arthritis. Completed, enrolled 684 participants across 1 site.
Detailed Summary
The special use-results surveillance is conducted in patients who have never been treated with Enbrel and in whom its long-term therapy may be instituted in the actual setting of use after marketing with the following objectives: 1. To examine the safety of long-term use of Enbrel including the occurrence of malignant tumors. 2. To confirm the efficacy of Enbrel in the long-term use.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesJapan
Collaborators--
Timeline
N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJul 2007
First PostedJul 2007
Primary CompletionApr 2013
TodayJul 2026
First PostedJul 18, 2007
Enrollment StartJul 1, 2007
Primary CompletionApr 1, 2013
TodayJul 2, 2026
Enrollment to primary: 5.8 yearsPosted 19.0 years ago
Interventions
Enbrel (etanercept)drug
Enbrel 10 to 25 mg twice a week subcutaneous injection